Welcome to our dedicated page for BillionToOne SEC filings (Ticker: BLLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BillionToOne, Inc. filings document the regulatory record for a public molecular diagnostics company commercializing QCT-based prenatal and oncology testing. Recent Form 8-K disclosures furnish operating results, financial guidance, Regulation FD presentation materials and executive compensation arrangements, including the company’s annual incentive plan and equity-based payment provisions.
Proxy materials describe annual meeting mechanics, stockholder voting matters, board governance and related governance disclosures. Together, the filings address the company’s clinical testing revenue categories, Class A common stock compensation framework, furnished earnings materials and governance matters relevant to its Nasdaq-listed operating-company status.
Hummingbird-affiliated investors have disclosed a significant stake in BillionToOne’s Class A common stock. A group of Belgian investment funds and their managing entities, together with individuals Firat Ileri, Barend Van den Brande and Lukas Decoster, report beneficial ownership of 7,887,237 shares, representing 19.6% of BillionToOne’s Class A common stock, based on 40,167,729 shares outstanding as of November 6, 2025.
The stake was built primarily through purchases of multiple series of redeemable convertible preferred stock between 2019 and 2024, plus common shares, for a total purchase price of $93,673,956.50. Those preferred shares converted into Class A common stock on a one-for-one basis immediately before BillionToOne’s initial public offering.
The reporting persons state that the shares were acquired for investment purposes. They indicate they may from time to time buy more, hold, or sell shares, and may communicate with BillionToOne’s management, board members, and other shareholders about strategy, operations, and financing alternatives. Firat Ileri also serves as a director of BillionToOne.
BillionToOne, Inc. (BLLN) insiders reported a large structural change in their holdings tied to the company’s initial public offering. Investment entities affiliated with Hummingbird funds and HB&Q NV converted multiple series of preferred stock into common stock on a one-for-one basis automatically immediately prior to the closing of BillionToOne’s IPO of Class A common stock, without any cash changing hands.
Immediately before the IPO, each share of common stock was then automatically reclassified into one share of Class A common stock under a Rule 16b-7–exempt reclassification. After these steps, the Hummingbird-affiliated entities reported Class A common stock positions, including 2,631,664 shares and 2,580,833 shares for certain funds. Humming Bird Ventures Management NV may be deemed to beneficially own shares held by the Hummingbird funds, while its partners, including Firat Ileri, Barend Van den Brande, and Lukas Decoster, disclaim beneficial ownership beyond their economic interests.
BillionToOne, Inc. filed an initial ownership report showing that several Hummingbird investment vehicles are 10% owners as of 11/05/2025. The filing reports indirect beneficial ownership of 179,999 shares of Common Stock and multiple series of convertible preferred stock, all held through Hummingbird funds. These preferred shares are convertible into Common Stock on a one-for-one basis and will automatically convert into Class A common stock immediately prior to the company’s initial public offering without additional payment. Humming Bird Ventures Management NV is the managing member of the Hummingbird funds and, along with certain partners, may be deemed to share voting and investment power, while the reporting persons disclaim beneficial ownership beyond their pecuniary interests.
BillionToOne, Inc. filed a current report stating that it issued a press release on January 12, 2026, reiterating its guidance for the full year ended December 31, 2025 and initiating guidance for full year 2026. This means the company confirmed its prior outlook for 2025 while also providing its initial expectations for 2026.
The company also noted that the investor presentation used at the 2026 J.P. Morgan Healthcare Conference on January 12, 2026 will be posted on the Investor page of its website under the “Events & Presentations” section.
BillionToOne, Inc. (BLLN) filed a Form 4 reporting equity award activity for its Chief Financial Officer. The filing shows stock options with exercise prices of $11.55 and $30.78 covering 175,000 and 75,000 shares, respectively. These options are listed both before and after a reclassification in connection with the company’s initial public offering of Class A common stock.
The filing explains that, under a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically converted into one share of Class A common stock immediately prior to completion of the IPO. The $11.55 options vest over four years, with 25% vested on January 8, 2025 and the rest in monthly installments over three years. The $30.78 options vest in equal monthly installments over four years starting September 15, 2025, contingent on continued service.